💨 Abstract

Travere Therapeutics reported a narrower-than-expected Q2 loss of $12.8 million, or 14 cents per share, beating analysts' predictions of a 28 cents per share loss. The company's revenue of $114.4 million also surpassed expectations, outdoing the $97.5 million forecast by seven analysts.

Courtesy: WTOP Staff